Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 590 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: acetylsalicylic acid Clear all

Conditions: Healthy
Interventions: intravenous diclofenac sodium (DIC075V), ketorolac, oral diclofenac (Cataflam), aspirin; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: WATCHMAN FLX Pro LAAC Device; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more

Conditions: Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
Interventions: Aspirin and/or Atorvastatin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: LVAD Implant, Aspirin 100mg, Placebo oral tablet; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more

Conditions: Coagulation Defects, Other and Unspecified
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 45 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease
Interventions: Dabigatran, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypertension
Interventions: Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: COPD, Emphysema, Emphysema or COPD
Interventions: dual anti-platelet therapy, Placebo; Combination Product · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fallopian Tube Cancer, Fallopian Tube Infection
Interventions: Aspirin 81 mg; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Asthma, Aspirin-induced
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Peripheral Vascular Diseases
Interventions: G-CSF, Placebo, Aspirin, Clopidogrel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions: Dupilumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Aspirin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Placebo; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Gastroduodenal Ulcer
Interventions: Naproxen, Aspirin, Celecoxib, Clopidogrel, Placebo; Drug
Lead sponsor: Research Associates of New York, LLP; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Preeclampsia Postpartum
Interventions: Aspirin tablet, Placebo oral capsule; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions: rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 86
States / cities: Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Dexamethasone, Aspirin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more

Conditions: Dietary Modification
Interventions: Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin; Dietary Supplement · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Angiogenesis
Interventions: Aspirin; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Stroke
Interventions: UPMC AF Prediction Model; Device
Lead sponsor: Samir Saba; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Platelet Aggregation, Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Accriva Diagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Jacksonville, Florida • Baltimore, Maryland

Conditions: Episodic Migraine, Chronic Migraine
Interventions: Aspirin (acetylsalicylic acid), Placebo; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma, Aspirin-Induced
Interventions: aspirin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation, Stroke
Interventions: Apixaban, aspirin; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 55 Years and older
Enrollment: 4,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 23
States / cities: Mesa, Arizona • Little Rock, Arkansas • Larkspur, California + 20 more

Search by objective public record fields.

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

SIMPLAAFY Clinical Trial

Subclinical Cardiovascular Disease in Psoriatic Disease

The ARIES HeartMate 3 Pump IDE Study

High-Shear Microfluidic Thrombosis Assay

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

Chlorthalidone and HCTZ Impacts on Platelet Activation

Anti-Platelets in Chronic Obstructive Pulmonary Disease

Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube

Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Postpartum Low-Dose Aspirin and Preeclampsia

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

Impact of Atrial Fibrillation Prediction Model on Prescribing Oral Anti-Coagulation in Patients With Cryptogenic Stroke

Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

Aspirin Resistance in Women With Migraine

Role of Inflammatory Mediators in AERD

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation